Evidence map›Paper›PMID 33558293›Full record

ArticleAntimicrobial agents and chemotherapy2021

Aiko Masuko, Iichiro Takata, Kiyoko Fujita, Hirotoshi Okumura, Fumihito Ushiyama, Hideaki Amada, Hiroyuki Sugiyama

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. In Vitro Activity of Zoliflodacin AgainstAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aiko MasukoPharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Iichiro TakataPharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Kiyoko FujitaPharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Hirotoshi OkumuraDrug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Fumihito UshiyamaChemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.ORCID 0000-0003-3122-8625
Hideaki AmadaChemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Hiroyuki SugiyamaPharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan hiro-sugiyama@taisho.co.jp.ORCID 0000-0002-0720-3906
Taisho Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gonorrhea is a common, sexually transmitted disease caused by

Indexed as

GonorrheaNeisseria gonorrhoeaeAnimalsAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVDrug Resistance, BacterialFluoroquinolonesMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVFluoroquinolonesantibiotic resistanceDNA gyraseDNA topoisomeraseenzyme inhibitorMAOQNeisseria gonorrhoeaeTP0480066

Identifiers

PMID33558293
PMCPMC8097434
OpenAlexW3128616689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.